Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Korman, Alan"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-17 z 17
    Tytuł:
    Enhanced protein production by engineered zinc finger proteins.
    Autorzy:
    Reik, Andreas
    Zhou, Yuanyue
    Collingwood, Trevor N.
    Warfe, Lyndon
    Bartsevich, Victor
    Kong, Yanhong
    Henning, Karla A.
    Fallentine, Barrett K.
    Zhang, Lei
    Zhong, Xiaohong
    Jouvenot, Yann
    Jamieson, Andrew C.
    Rebar, Edward J.
    Case, Casey C.
    Korman, Alan
    Li, Xiao-Yong
    Black, Amelia
    King, David J.
    Gregory, Philip D.
    Pokaż więcej
    Źródło:
    Biotechnology & Bioengineering; Aug2007, Vol. 97 Issue 5, p1180-1189, 10p
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
    Autorzy:
    Martinez Forero I; Centro de Investigacion Medica Aplicada, Universidad de Navarra, Avda Pio XII, 55, 31008 Pamplona, Spain.
    Okada H
    Topalian SL
    Gajewski TF
    Korman AJ
    Melero I
    Pokaż więcej
    Źródło:
    Journal of translational medicine [J Transl Med] 2012 May 28; Vol. 10, pp. 108. Date of Electronic Publication: 2012 May 28.
    Typ publikacji:
    Congress
    MeSH Terms:
    Societies, Medical*
    Immunotherapy/*methods
    Neoplasms/*immunology
    Neoplasms/*therapy
    Animals ; Antibodies, Monoclonal/immunology ; Cancer Vaccines/immunology ; Cancer Vaccines/therapeutic use ; Combined Modality Therapy ; Humans ; Immune System/immunology ; Immune System/pathology ; Mice ; Neoplasms/prevention & control
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
    Autorzy:
    Chang, Katherine C
    Burnham, Carey-Ann
    Compton, Stephanie M
    Rasche, David P
    Mazuski, RichardJ
    SMcDonough, Jacquelyn
    Unsinger, Jacqueline
    Korman, Alan J
    Green, Jonathan M
    Hotchkiss, Richard S
    Mazuski, Richard J
    McDonough, Jacquelyn S
    Pokaż więcej
    Źródło:
    Critical Care; 2013, Vol. 17 Issue 1, pR85-R85, 1p
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
    Autorzy:
    Gardiner, David
    Lalezari, Jay
    Lawitz, Eric
    DiMicco, Michael
    Ghalib, Rheem
    Reddy, K. Rajender
    Chang, Kyong-Mi
    Sulkowski, Mark
    Marro, Steven O’
    Anderson, Jeffrey
    He, Bing
    Kansra, Vikram
    McPhee, Fiona
    Wind-Rotolo, Megan
    Grasela, Dennis
    Selby, Mark
    Korman, Alan J.
    Lowy, Israel
    Pokaż więcej
    Temat:
    MONOCLONAL antibodies
    CHRONIC hepatitis C
    APOPTOSIS
    DEATH receptors
    GENE expression
    LIGANDS (Biochemistry)
    T cells
    PLACEBOS
    Źródło:
    PLoS ONE; May2013, Vol. 8 Issue 5, p1-11, 11p
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
    Autorzy:
    Wolchok JD; Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. />Hodi FS
    Weber JS
    Allison JP
    Urba WJ
    Robert C
    O'Day SJ
    Hoos A
    Humphrey R
    Berman DM
    Lonberg N
    Korman AJ
    Pokaż więcej
    Źródło:
    Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2013 Jul; Vol. 1291, pp. 1-13. Date of Electronic Publication: 2013 Jun 17.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Antibodies, Monoclonal/*therapeutic use
    Antineoplastic Agents/*therapeutic use
    Melanoma/*drug therapy
    Skin Neoplasms/*drug therapy
    Animals ; Antibodies, Monoclonal/immunology ; Antineoplastic Agents/immunology ; Clinical Trials as Topic/methods ; Humans ; Immunotherapy/methods ; Ipilimumab ; Melanoma/immunology ; Melanoma/mortality ; Skin Neoplasms/immunology ; Skin Neoplasms/mortality ; Survival Rate/trends ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
    Autorzy:
    Chang, Katherine C.
    Burnham, Carey-Ann
    Compton, Stephanie M.
    Rasche, David P.
    Mazuski, Richard J.
    McDonough, Jacquelyn S.
    Unsinger, Jacqueline
    Korman, Alan J.
    Green, Jonathan M.
    Hotchkiss, Richard S.
    Pokaż więcej
    Temat:
    SEPSIS
    INTENSIVE care patients
    MORTALITY
    ANTI-infective agents
    FUNGEMIA
    IMMUNOLOGIC diseases
    IMMUNOSUPPRESSION
    Źródło:
    Critical Care; 2013, Vol. 17 Issue 3, p1-14, 14p, 8 Graphs
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
    Autorzy:
    Gubin MM; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Zhang X; Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Schuster H; Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany.
    Caron E; Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland.
    Ward JP; 1] Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA [2] Department of Medicine, Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Noguchi T; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Ivanova Y; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Hundal J; The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA.
    Arthur CD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Krebber WJ; ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands.
    Mulder GE; ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands.
    Toebes M; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
    Vesely MD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Lam SS; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Korman AJ; Bristol-Myers Squibb, 700 Bay Road, Redwood City, California 94063, USA.
    Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
    Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
    Sharpe AH; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts 02115, USA.
    Pearce EL; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Schumacher TN; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
    Aebersold R; 1] Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland [2] Faculty of Science, University of Zurich, Zurich, 8093 Zurich, Switzerland.
    Rammensee HG; Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany.
    Melief CJ; 1] ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands [2] Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333ZA Leiden, The Netherlands.
    Mardis ER; 1] The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA [2] Department of Genetics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Gillanders WE; Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Artyomov MN; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Schreiber RD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
    Pokaż więcej
    Źródło:
    Nature [Nature] 2014 Nov 27; Vol. 515 (7528), pp. 577-81.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Immunotherapy*
    Antibodies, Monoclonal/*therapeutic use
    Antigens, Neoplasm/*genetics
    Antigens, Neoplasm/*immunology
    CD8-Positive T-Lymphocytes/*immunology
    Cancer Vaccines/*therapeutic use
    Cell Cycle Checkpoints/*immunology
    Sarcoma/*therapy
    Animals ; Epitopes/genetics ; Male ; Mice ; Sarcoma/immunology ; Vaccines, Synthetic/therapeutic use
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Evolving synergistic combinations of targeted immunotherapies to combat cancer.
    Autorzy:
    Melero I; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
    Berman DM; Bristol-Myers Squibb, 3551 Lawrenceville Princeton, New Jersey 08648, USA.
    Aznar MA; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
    Korman AJ; Bristol-Myers Squibb Biologics Discovery California, 700 Bay Road, Redwood City, California 94063, USA.
    Pérez Gracia JL; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
    Haanen J; The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Pokaż więcej
    Źródło:
    Nature reviews. Cancer [Nat Rev Cancer] 2015 Aug; Vol. 15 (8), pp. 457-72.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Immunotherapy*
    Neoplasms/*therapy
    Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/metabolism ; Clinical Trials as Topic ; Combined Modality Therapy ; Humans ; Molecular Targeted Therapy ; Neoplasms/immunology ; Tumor Microenvironment/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.
    Autorzy:
    Chew GM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
    Fujita T; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
    Webb GM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Burwitz BJ; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Wu HL; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Reed JS; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Hammond KB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Clayton KL; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
    Ishii N; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
    Abdel-Mohsen M; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
    Liegler T; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
    Mitchell BI; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
    Hecht FM; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
    Ostrowski M; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
    Shikuma CM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
    Hansen SG; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Maurer M; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
    Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
    Deeks SG; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
    Sacha JB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
    Ndhlovu LC; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2016 Jan 07; Vol. 12 (1), pp. e1005349. Date of Electronic Publication: 2016 Jan 07 (Print Publication: 2016).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    CD4-Positive T-Lymphocytes/*immunology
    CD8-Positive T-Lymphocytes/*immunology
    HIV Infections/*immunology
    Receptors, Immunologic/*immunology
    Animals ; B7-H1 Antigen/immunology ; Cell Separation ; DNA, Viral/analysis ; Disease Progression ; Flow Cytometry ; Humans ; Lymphocyte Activation/immunology ; Macaca mulatta ; RNA, Viral/analysis ; Simian Acquired Immunodeficiency Syndrome/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Autorzy:
    Selby MJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Engelhardt JJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Johnston RJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Lu LS; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Han M; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Thudium K; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Yao D; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Quigley M; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Valle J; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Wang C; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Chen B; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Cardarelli PM; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Blanset D; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Korman AJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2016 Sep 09; Vol. 11 (9), pp. e0161779. Date of Electronic Publication: 2016 Sep 09 (Print Publication: 2016).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Immunotherapy*
    Antibodies, Monoclonal/*therapeutic use
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Melanoma/*drug therapy
    Animals ; Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/metabolism ; Cell Line, Tumor ; Cells, Cultured ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/therapy ; Combined Modality Therapy ; Disease Models, Animal ; Female ; Humans ; Ipilimumab ; Lymphocytes/immunology ; Lymphocytes/metabolism ; Macaca fascicularis ; Melanoma/metabolism ; Melanoma/therapy ; Mice ; Mice, Inbred C57BL ; Nivolumab ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; T-Lymphocytes, Regulatory/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Autorzy:
    Selby MJ
    Engelhardt JJ
    Johnston RJ
    Lu LS
    Han M
    Thudium K
    Yao D
    Quigley M
    Valle J
    Wang C
    Chen B
    Cardarelli PM
    Blanset D
    Korman AJ
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2016 Nov 18; Vol. 11 (11), pp. e0167251. Date of Electronic Publication: 2016 Nov 18 (Print Publication: 2016).
    Typ publikacji:
    Published Erratum
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
    Autorzy:
    Colston E; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
    Grasela D; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
    Gardiner D; Infectious Diseases Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America.
    Bucy RP; Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
    Vakkalagadda B; Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Hopewell, New Jersey, United States of America.
    Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
    Lowy I; Translational Science and Clinical Oncology, Regeneron Pharmaceuticals, Tarrytown, New York, United States of America.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2018 Jun 07; Vol. 13 (6), pp. e0198158. Date of Electronic Publication: 2018 Jun 07 (Print Publication: 2018).
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    CTLA-4 Antigen/*immunology
    HIV Infections/*drug therapy
    HIV-1/*immunology
    Ipilimumab/*administration & dosage
    Viremia/*drug therapy
    Adult ; CD4 Lymphocyte Count ; CTLA-4 Antigen/antagonists & inhibitors ; Dose-Response Relationship, Drug ; Female ; HIV Infections/immunology ; HIV Infections/metabolism ; HIV Infections/virology ; Humans ; Ipilimumab/adverse effects ; Ipilimumab/pharmacokinetics ; Male ; Maximum Tolerated Dose ; Middle Aged ; RNA, Viral/blood ; Viremia/immunology ; Viremia/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Expression of LAG‐3 and efficacy of combination treatment with anti‐LAG‐3 and anti‐PD‐1 monoclonal antibodies in glioblastoma.
    Autorzy:
    Harris‐Bookman, Sarah
    Mathios, Dimitrios
    Martin, Allison M.
    Xia, Yuanxuan
    Kim, Eileen
    Xu, Haiying
    Belcaid, Zineb
    Polanczyk, Magdalena
    Barberi, Theresa
    Theodros, Debebe
    Kim, Jennifer
    Taube, Janis M.
    Burger, Peter C.
    Selby, Mark
    Taitt, Corina
    Korman, Alan
    Ye, Xiaobu
    Drake, Charles G.
    Brem, Henry
    Pardoll, Drew M.
    Pokaż więcej
    Źródło:
    International Journal of Cancer; Dec2018, Vol. 143 Issue 12, p3201-3208, 8p
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
    Autorzy:
    Maas, Ralph Ja
    Hoogstad-van Evert, Janneke S
    Van der Meer, Jolien Mr
    Mekers, Vera
    Rezaeifard, Somayeh
    Korman, Alan J
    de Jonge, Paul Kjd
    Cany, Jeannette
    Woestenenk, Rob
    Schaap, Nicolaas Pm
    Massuger, Leon F
    Jansen, Joop H
    Hobo, Willemijn
    Dolstra, Harry
    Pokaż więcej
    Temat:
    KILLER cells
    OVARIAN cancer
    INTERFERON gamma
    BLOOD cells
    Źródło:
    OncoImmunology; 2020, Vol. 9 Issue 1, p1-11, 11p
    Czasopismo naukowe
    Szczegóły
      Wyświetlanie 1-17 z 17

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies